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A B S T R A C T
Background Attention-deficit/hyperactivity disorder (ADHD) is among the most common psychiatric
disorders of childhood that often persists into adulthood and old age. Yet ADHD is currently
underdiagnosed and undertreated in many European countries, leading to chronicity of symptoms and
impairment, due to lack of, or ineffective treatment, and higher costs of illness.
Methods The European Network Adult ADHD and the Section for Neurodevelopmental Disorders
Across the Lifespan (NDAL) of the European Psychiatric Association (EPA), aim to increase awareness and
knowledge of adult ADHD in and outside Europe. This Updated European Consensus Statement aims to
support clinicians with research evidence and clinical experience from 63 experts of European and other
countries in which ADHD in adults is recognized and treated.
Results Besides reviewing the latest research on prevalence, persistence, genetics and neurobiology of
ADHD, three major questions are addressed: (1) What is the clinical picture of ADHD in adults? (2) How
should ADHD be properly diagnosed in adults? (3) How should adult ADHDbe effectively treated?
Conclusions ADHD often presents as a lifelong impairing condition. The stigma surrounding ADHD,
mainly due to lack of knowledge, increases the suffering of patients. Education on the lifespan
perspective, diagnostic assessment, and treatment of ADHD must increase for students of general and
mental health, and for psychiatry professionals. Instruments for screening and diagnosis of ADHD in
adults are available, as are effective evidence-based treatments for ADHD and its negative outcomes.
More research is needed on gender differences, and in older adults with ADHD.
© 2018 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction: the European Network Adult ADHD
The European Network Adult ADHD (ENAA) was founded in
2003 to help improve the diagnosis and treatment of ADHD in
adults in Europe and beyond. ENAA represents mental health care
professionals and researchers from 28 countries with expertise on
ADHD in adults (www.eunetworkadultadhd.com). The
Section Neurodevelopmental Disorders Across the Lifespan (NDAL)
of the European Psychiatric Association (EPA) joined our effort to* Corresponding author at: European Network Adult ADHD, VUMc, Amsterdam,
EPA, The Netherlands.
E-mail address: s.kooij@psyq.nl (J.J.S. Kooij).provide this update of our first Consensus Statement on adult
ADHD published in 2010 [1].
1.1. Objectives of the updated consensus statement for clinicians
Despite strong evidence on the clinical presentation, genetics,
neurobiology, the burden of the disorder, and on safe and effective
treatment for ADHD in adults, many people are still under-
diagnosed and undertreated. Specialized clinical services remain
scarce in most parts of the world, including Europe [2,3]. Our aim is
to provide an update of the literature on assessment and treatment
of adult ADHD to [1] increase awareness on ADHD as an impairing
life-long neurodevelopmental condition up to old age [2]; update
the assessment procedure for diagnosing ADHD in adults; and [3]
give updated recommendations for appropriate treatments.
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Creating a Consensus Statement does not follow the same
procedure as required for the development of a guideline, such
as systematic reviews using formal ratings of the evidence.
Most of the authors participated in the development of a first
Consensus Statement on adult ADHD in 2010, and were asked
to provide an update of the previous text based on new findings
in the literature since the time of publication. Subgroups
dealing with different subjects were formed. The subgroups
reached consensus on the text among themselves before
sending it to the first author. The first author put all paragraphs
together and edited the text with the help of a few other
coauthors (DW, SY, PA, DB). This draft of the manuscript was
send to all authors for their comments. The first author
checked the comments and implemented adjustments into the
text, and send the final version to all authors for agreement. All
authors agreed with the final version.
2. Heritability and environment
Family, twin and adoption studies from the last 20 years show
that ADHD is a familial disorder with high heritability, indicating
that a significant genetic component influences risk for the
disorder [4–12]. Environmental factors such as severe institu-
tional deprivation are also likely to play a role, either as main
causal factors in a few cases [13] or by interaction with genetic
risks. Family studies indicate a risk to first-degree relatives of 4–5
fold the population rate or higher, with prevalence rates around
20% among first degree relatives [14]. Data on ADHD in children
and adolescents find average heritability of around 76% [12].
Studies in adult twins using self-rated ADHD symptoms
consistently report lower estimates of heritability, around 30–
40% [15–17]. One reason for lower heritability of adult self-
reported ADHD symptoms may be from the use of self-ratings.
These lead to lower estimates of heritability compared to
informant ratings regardless of age, perhaps due to variable
levels of awareness among individuals rating their own ADHD
symptoms [18,19]. Studies combining data across informants
[20], or using clinical diagnostic information [21] find heritability
estimates for adult ADHD in the same range (70–80%) as for
children [22].
2.1. Candidate genes
Early molecular genetic studies of ADHD in children reported
genetic associations with several candidate genes. Genetic variants
within or near the D4 and D5 dopamine receptor genes provided
the most consistent findings supported by meta-analysis [23].
Other specific candidate genes were implicated in the early studies
[12,24,25], but none have provided consistent evidence or been
replicated in more recent large-scale genome wide association
studies. Taken together the traditional neurotransmitter system
genes appear to explain only a small amount of the variance in
ADHD [26]. There is also some converging evidence for the role of
genes that fit into a neurodevelopmental network involved in
directed neurite outgrowth [27].
2.2. Genome wide association studies (GWAS)
More recent findings have emerged from genome-wide
association studies [28]. The most recent dataset reported included
over 20,000 ADHD cases and 35,000 controls. These data were used
to estimate that around 30% of the heritability of ADHD is
explained by common genetic variation. In total, twelve loci
achieved genome-wide significance, including FOXP2; notablebecause prior work had implicated it in adult ADHD [29]. These
findings place ADHD firmly on the path to detecting very large
numbers of associated common genetic variants as more samples
are accrued.
LD regression analyses that estimate genetic correlations
between disorders find strong genetic links between ADHD and
a range of outcomes including educational performance, depres-
sion, obesity, smoking and lung cancer [28]. A further finding is the
very strong genetic correlation between the diagnosis of ADHD,
and trait scores in general population samples, demonstrating that
ADHD represent the extreme of a continuously distributed trait in
the general population [30]. These finding confirm the polygenic
nature of genetic liability to ADHD.
Rare copy number variants (CNVs) occurring on less than 1% of
chromosomes are also known to play a role in a subset of
individuals with ADHD [31,32]. CNVs were found to be 2-fold more
common in children with ADHD within the normal IQ range, and 6-
fold higher in those with IQs below 70 [32]. Specific genes
suggested as CNVs linked to ADHD include the nicotinic alpha-7
acetylcholine receptor gene (e.g., [33]), several glutamate receptor
genes [34] and neuropeptide-Y [35], although these findings
remain inconsistent and hard to verify due to low frequency in the
population.
2.3. Molecular genetic studies of adult ADHD
Molecular genetic studies of adult ADHD are less advanced,
but are expected to confirm some genetic associations identified
in childhood and find other genetic associations related to
persistence or remission of ADHD in adult life [20]. A preliminary
report at the International Neuropsychology meeting (Wash-
ington, 2018) found the genetic correlation between child and
adult ADHD to be greater than 80%. Most of the current research
has been coordinated in Europe by Barbara Franke from the
Netherlands for the International Multicentre Persistent ADHD
Collaboration (IMPACT) group. This collaboration has successfully
generated a multi-site sample of more than 3500 patients and
continues to grow. To date several publications highlight
potential associations with adult ADHD, some but not all of
which are shared with genetic association findings in children
[36–42].
2.4. Environmental factors
It has been known for a long time that environmental factors
are associated with ADHD [43], particularly prenatal risk factors
such as exposure to alcohol and drugs, valproic acid, high blood
pressure, maternal stress during pregnancy, as well as preterm
birth and low birth weight [44–46]. However sophisticated
study designs are needed to clarify whether these association
reflect direct effects of the environmental exposure or reflect
genetically correlated risk measures. For example, although
smoking during pregnancy is clearly associated with offspring
ADHD, this association appears to be entirely accounted for by
the genetic correlation between maternal smoking and off-
spring ADHD [47]. In contrast, evidence from Romanian
adoptees suggests that severe early deprivation is causally
related to ADHD in a dose dependent way [13]. Gene by
environment interactions (G x E) have been proposed and may
explain some of the missing heritability seen between
heritability estimates derived from twin (0.76) and molecular
genetic (0.22) data. However, to date no G x E effects have been
clearly identified. The findings to date indicate that much more
work is needed to understand the interplay between genetic
and environmental risks.
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3.1. Neuro-imaging: evidence for atypical gray and white matter areas
Structural brain scans of adults with ADHD showed grey matter
abnormalities in several brain areas, including the right frontal and
prefrontal areas [48,49], anterior cingulate [50–52], the basal
ganglia and the cerebellum [53–56] with some preliminary
research also showing abnormalities of the visual cortex [57].
Additionally, cortical thickness was found to be reduced in adult
ADHD [56,58,59]. Some evidence suggests that grey matter
abnormalities, in some subcortical regions, are more pronounced
in children than adults. This might reflect the effects of age,
medication, intrinsic heterogeneity of the ADHD syndrome, or a
combination thereof [51,60–64].
Despite these reported findings the latest mega-analysis
conducted by the Enigma consortium found no significant
differences in brain structure between adult ADHD and controls;
although, small but significant differences were found in children
for subcortical regions including the accumbens, amygdala,
caudate, hippocampus, putamen and intracranial volume with
effects ranging from d = .10–.15 [65]. These findings indicate that
while there are structural changes in subcortical brain regions in
ADHD in children, these are relatively subtle effects that dissipate
with increasing age.
Diffusion tensor imaging (DTI) highlighted that white matter
tracts, including fronto-occipital, fronto-striatal, temporal and
temporo-occipital fasciculi and part of the corpus callosum, bear
microstructural abnormalities [66–71]. Additionally, some find-
ings also linked microstructure variability to symptomatology such
that greater inattention but not hyperactivity-impulsivity was
associated with significantly lower fractional anisotropy (that is
lower microstructural integrity) in the left uncinate and inferior
fronto-occipital fasciculi compared to controls [70]. These results
indicate that structural deficits in ADHD are not just confined to
specific regions but involve interconnections among large scale
brain networks [68,71–73].
3.2. Functional neuroimaging
Regarding functional MRI (fMRI) studies, task-based and
resting-state findings converge. Meta-analyses show that ADHD
is associated with dysfunctions in several domain-specific fronto-
striatal and fronto-cerebellar neural networks. Thus a meta-
analysis of 39 child and 16 adult ADHD fMRI studies concluded that
in ADHD there are significant dysfunctions in multiple neuronal
systems involved in higher-level cognitive functions [74]. These
include hypoactivations in the frontoparietal executive control
network, putamen, and ventral attention network, which is
consistent with the classical model of ADHD as a disorder of
deficient fronto-striatal activation.
Hyperactivations are also seen in regions of the default mode
and visual networks, which support the contemporary view that
ADHD is associated with faulty regulation of relationships between
default mode and task positive networks. Similar findings come
from meta-analyses, which show consistent underactivation in
inferior fronto-striatal networks during cognitive tasks [75], in
dorsolateral fronto-striato-parietal networks during attention
tasks [75], and in fronto-cerebellar networks for timing functions
[76]; in addition to abnormally enhanced activation in default
mode regions [76].
The recent focus on resting state fMRI (RS-fMRI) identified
multiple intrinsic neural circuits, reflecting functional connectivity
within and between regions which is continuously encoded in the
spontaneous activity of the brain [77]. The intrinsic fronto-parietal,
dorsal attentional, visual, motor and default mode networks alloverlap with regions showing differential task activations during
inhibition, attention, or working memory tasks in ADHD compared
to controls [78]. Despite the wealth of established findings from
fMRI and RS-fMRI studies of ADHD, cross-sectional neuroimaging
data is correlational in nature and causal inferences cannot yet be
made.
More recently outcome studies of children diagnosed with
ADHD has been able to compare functional brain change in adults
with persistent and remitted ADHD and compare these to age-
matched controls. The largest such follow-up study to date, of 205
children with ADHD, found that persistence of ADHD was
associated with loss of the balance of connections within the
default mode network, and connections between the default mode
and those supporting attention and cognitive control. In contrast
there were no differences in these networks between those whose
ADHD had remitted and non-ADHD controls [79].
Overall, despite the wealth of established findings from fMRI and
RS-fMRI studies of ADHD, cross-sectional neuroimaging data is
correlational in nature and causal inferences cannot yet be made.The
finding that certain functional brain changes are seen to differ
between persistent compared to remitted cases of childhood ADHD
sheds some light on likely causal processes, but further longitudinal
data is still required before firm conclusions can be drawn.
3.3. Neuropsychological and electrophysiological tests
As a group, individuals with ADHD are characterized by altered
neuropsychological functioning across a variety of executive
function (EF) measures. However, thus far there is neither a
neurobiological nor a neuropsychological test (battery) for ADHD
with sufficient positive predictive power to establish the diagnosis
at the individual level [80]. In one study, the vast majority of
neuropsychological instruments showed poor discriminative
ability compared to clinical assessment measures such as the
ASRS Screener v1.1 and the DIVA 2.0 Diagnostic Interview for
ADHD in adults, with an overall classification accuracy ranging
from 53% to 66% [81]. Nevertheless, when used in combination
with the DIVA 2.0, objective cognitive performance tests measur-
ing omission and commission errors, and physical activity, were
found to increase the correct classification of adult ADHD [81].
There is currently insufficient evidence to warrant the use of
neuropsychological testing to determine the diagnosis of ADHD
[82] or to predict impairment in major life domains [83].
Moreover, clinicians should also be aware of the possibility that
a few individuals may feign ADHD symptoms to gain external
incentives, like stimulant medication or special academic accom-
modations. There is some evidence supporting the effectiveness of
performance validity tests (PVTs) in differentiating between
genuine and feigned ADHD compared to rating scales [84].
Electrophysiological studies suggest that brain dysfunctions are
involved in the central components of ADHD in both children and
adults [85–89], although the finding of increased DAT density
remains controversial [90,91].
Data from Electro Encephalography (EEG) is relatively scarce in
adult ADHD. Generally, EEG studies of ADHD find similar deficits in
adults and children, while some findings change with age and
might be sensitive to developmental changes [92]. Despite US Food
and Drug Administration approval of an EEG device (2013) that
assists in the diagnosis of ADHD subtypes [93–95], this remains
controversial [96]. EEG tests are not sufficiently accurate but could
be useful to increase diagnostic certainty.
4. ICD and DSM criteria for ADHD
There are two diagnostic manuals used to diagnose ADHD: The
Diagnostic and Statistical Manual of Mental Disorders (DSM) and
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Health Problems (ICD). As ADHD has been recognized as a disorder
affecting individuals across the lifespan, the diagnostic criteria for
adolescents and adults have been adjusted in the DSM-5,
published in May 2013:
1) ADHD is now in the chapter Neurodevelopmental Disorders,
which includes conditions associated with factors affecting the
brain development.
2) Diagnostic criteria have been adapted by adding some examples
describing how ADHD symptoms are expressed across the
lifespan.
3) The age of onset criteria has been changed requiring several
symptoms to be present before age of 12 years, instead of some
symptoms and impairment by age 7.
4) The term “subtype” has been replaced by “presentation”,
reflecting the variation of ADHD symptoms within the same
individual during the lifespan.
5) The symptom threshold required has been reduced to 5
symptoms instead of six for older adolescents and adults
(>17 years) in either the inattention or hyperactive/impulsive
domain.
6) Criteria requiring significant impairment has been modified to
“clear evidence that symptoms interfere with or reduce the
quality of social, academic and occupational functioning”, with
specifiers regarding severity level.
7) The presence of Autism Spectrum Disorder (ASD) is no longer an
exclusion criterion, consistent with evidence showing their
frequent co-occurrence.
8) ADHD Not Otherwise Specified (NOS) has been changed into
Other Specified ADHD and Unspecified ADHD.
The revision of ICD-10, ICD-11 has been published in June 2018.
ICD-11, developed by the World Health Organization now refers to
ADHD as Attention Deficit Hyperactivity Disorder, instead of
previously Hyperkinetic Disorder (HKD) [97]. It now uses similar
requirements as the DSM-5 regarding age of onset, and the same 3
presentation types. In Europe, ICD codes are often used for
statistics on mortality, morbidity and by insurance agencies for
health-related reimbursements [98], whereas DSM is primarily
used in clinical practice by licensed mental health care profes-
sionals [99].
The diagnostic assessment starts by evaluation of self-reported
symptomatology. The clinical interview is essential for diagnosing
ADHD in adults, which investigates the characteristic symptoms
and impairments of ADHD in both childhood and adulthood. In
children and adolescents, informants’ ratings are higher correlated
with heritability and cognitive and EEG findings than self-ratings
[19]. Also prevalence and persistence rates increase when parent
reports are used [19]. In adults this may be slightly different, as
some research shows that the adult patient is the best informant
[100]. The presence of a family member however (a parent and/or
the partner) during the assessment can still provide valuable
additional information, e.g. on severity and its translation into
daily activities.
There is compelling evidence that a cut-off of four current
symptoms is the most appropriate for an adult diagnosis [101,102].
However, due to concern about the possibility of an artificial
increase in the prevalence of the disorder, DSM-5 lowered the
threshold for diagnosing ADHD from six to five symptoms for those
older than 17 years of age. Several items have been expanded by
some illustrative examples to facilitate the recognition of the
disorder throughout development. Although not included in
thecriteria as such, behaviors reflecting executive dysfunction
usually appear clearly during the assessment, when patients
describe problems with organization, facing daily responsibilities,solving problems, managing time and self-regulating (inhibiting)
behaviors.
DSM-5 also highlights the importance of mood lability and
emotional dysregulation as “an associated feature that support the
diagnosis”. Although emotional dysregulation may dominate the
clinical presentation [103–105], it is not a criterion for classifying
individuals as it lacks specificity, occurring in many other mental
health conditions.
DSM-IV required that symptoms and impairment were
present before age 7, but as research demonstrated no differences
between children with an age of onset before and after age 7 [106]
this criterion was changed to several symptoms by age 12. Similar
findings have also been reported regarding adults reporting later-
onset of symptoms [107,108], and there is disagreement both
within and across sources concerning recall of symptom onset
[109]. The fact that adults with ADHD frequently fail to recall
childhood behavior led to the suggestion that clinicians take note
that the onset of the disorder was during the developmental
period, or they should use age 16 years as the upper age limit.
Using this criteria captured all cases of childhood ADHD and 99%
of adults with the disorder [110]. The decision of DSM-5 to extend
the age of onset to 12 instead of 16 may have a negative impact on
adults with ADHD who have difficulties with retrospective recall
of childhood behaviors, and may not receive the diagnosis for this
reason. This may be particularly true for those who had some
compensation due to high intelligence, or lived in a highly
structured or supported environment, or presented predomi-
nantly with inattentive symptoms. In such cases, the presence of a
collateral informant (generally a parent or spouse) is of great
value. Many adults with ADHD that are used to their lifelong
symptoms, have limited awareness of how ADHD symptoms
adversely impact their interpersonal relationships and affect their
life; some reporting higher symptoms but lower impairments or
vice versa.
Such inconsistency has been attributed to a lack of introspec-
tion and an incoherent self-view [111,112], and supports the utility
of a collateral informant. If a significant other is not available,
school reports or social care reports may be helpful.
4.1. Clinical picture
4.1.1. Inattention and hyperfocus
Patients with mainly inattention problems are often slow to
think and formulate due to distractions. They may formulate things
in a long-winded and tangential way, losing themselves in
irrelevant details and having difficulty making decisions. A
difficulty for the clinician is that this may hinder the diagnostic
assessment. Patients may also over-concentrate or ‘hyperfocus’.
This phenomenon most commonly occurs when engaged in
activities that the patient finds very interesting and/or provide
instant gratification, such as computer games or online chatting.
For such activities, concentration may last for hours on end, in a
very focused manner.
4.1.2. Hyperactivity
With respect to hyperactivity, adults do not present in the same
way as children. Their hyperactivity usually manifests in a more
subtle way. Clinicians need to assess their feelings of restlessness. A
first impression of mobility is not definitive; sitting calmly during
the diagnostic assessment does not exclude any ADHD. Hyperac-
tivity in adults often manifests itself as feelings of continuous inner
restlessness or agitation, talking too much, ceaseless mental
activity, not being able to relax properly or needing alcohol or
drugs to relax and/or sleep. Hyperactivity and/or restlessness may
be temporarily relieved by the patient engaging in excessive sport
activities, and in such cases the person may suffer physical
Table 1
Examples of ADHD-related symptoms.
Inattention  Forgetfulness
 Distractibility
 Chaotic presentation
 Difficulty organizing & planning
 Difficulty listening
 Difficulty with punctuality (arriving either too late or too
early)
 Temporary hyperfocus for highly salient tasks, but no
control of attention when required or for many essential
activities of daily life
 Getting lost in details
 Doubtfulness – unable to make decisions or solve
problems
 Needing too much time to complete tasks
 Difficulty starting and finishing tasks
 Mind Wandering:
 Mental restlessness
 Unrelated spontaneous thoughts, constantly on the go,
jumping and flitting, multiple thoughts at the same
time
 Associative thinking
Hyperactivity  (Inner) Restlessness
 Difficulty relaxing
 Pacing up and down
 Talking too much and too loud
 Fidgeting, rocking or tapping
 Not being able to bear an office job because of
restlessness
 Knocking things over because of excessive mobility
 Being able to sit still but this comes with muscle strain
 Restless sleep
Impulsivity  Acting without thinking
 Difficulty waiting turn – linked to feelings of irritability
 Blurting things out that cause distress to others
 Interrupting others
 Impatience and difficulty waiting turn
 Spending too much
 Walking out of jobs
 Starting relationships quickly
 Not being able to postpone gratification
 Sensation seeking and risk taking behaviors
 Binge eating
Emotional
dysregulation
 Mood lability
 Low frustration tolerance
 Emotional impulsivity
 Irritability
 Anger outbursts
 Premenstrual increase of symptoms
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due to sustained injuries.
4.1.3. Impulsivity
Impulsive behavior and associated interpersonal conflicts often
have consequences for relationships with family, friends, colleagues
and employers. It may also seriously impact on personal finance
when impulsive spending causes debt. Impulsive binge behaviors
may also be present (e.g. binge eating), often to combat restlessness
or due to a need for immediate gratification. Closely related to
impulsivity are ‘sensation seeking’ behaviors when patients may
seek out excitement from novel and thrilling stimuli. These often
involve risk taking behaviors such as playing with fire, reckless
driving, sexual risks, and provocative behavior leading to fights.
4.1.4. Emotional dysregulation
Emotional dysregulation is listed by DSM-5 as a characteristic
feature of ADHD, supporting the diagnosis [113]. The type of
emotional dysregulation seen in ADHD has been characterized as
deficient self-regulation of emotional symptoms such as irritabili-
ty, frustration and anger [114], and low frustration tolerance,
temper outbursts, emotional impulsivity, and mood lability [115].
Emotional dysregulation in ADHD is different from episodic
symptoms such as marked sustained irritability occurring within
the context of altered mood states, such as an episode of
depression or mania. In ADHD, emotional symptoms tend to
reflect short lived exaggerated changes, often in response to daily
events, with rapid return to baseline within a few hours [114].
Whether the type of emotional instability seen in ADHD is
qualitatively different to that seen in other chronic conditions such
as borderline personality disorder or post-traumatic stress remains
unclear.
4.1.5. Excessive mind wandering
Another common feature of adult ADHD is excessive mind
wandering, also referred to as mental restlessness [116–118]. In
DSM-5 mind wandering is briefly mentioned as the occurrence of
unrelated thoughts. Although mind wandering is a universal
experience, some forms of mind wandering are detrimental
because they interfere with task performance. Adults with ADHD
frequently report a distractible mental state with multiple
unrelated thoughts that are constantly on the go and jump from
one topic to another [119,120]. Mind wandering is also a feature of
other mental health disorders such as depressive or obsessive
disorders. However, in ADHD mind wandering is characterized by
unfocused, short lived distractible thoughts with no pattern of
repeated thoughts or abnormality of content. Research found that
excessive mind wandering was strongly correlated with ADHD
symptoms, was a strong predictor of the diagnosis (sensitivity and
specificity around 90% for case-control differences), co-varied with
ADHD symptoms over a 6-month period, and was a better
predictor of ADHD-related impairments than the inattentive and
hyperactive-impulsive symptoms of ADHD [120]. In ADHD it can
be measured using the Mind Excessively Wandering Scale
[116,118,120] (Table 1).
4.1.6. Behavioral self-regulation (executive function deficits)
ADHD has been described as a disorder of executive functions
such as inhibition and working memory. These include problems
organizing, prioritizing and initiating work; focusing, sustaining
and shifting attention to tasks; regulating alertness, sustaining
effort and processing speed; managing frustration and regulating
emotions; utilizing working memory and accessing recall; and
monitoring and self-regulation of behavior [121,122]. Although
clinically these are good descriptions of the types of difficulties
experienced by adults with ADHD, behavioral measures do notcorrelate well with cognitive or neuropsychological tests of
executive control [121–123]. A distinction needs to be made
between rating scale measures of behaviours reflecting self-
regulation of behavior referred to as EF (behavioral) deficits, and
the results of neurocognitive tests of EFs such as working memory
and inhibition. Neuropsychological test scores reflecting executive
functioning lack ecological validity in that they have no significant
relationship to behavioural rating scale measures of EF [124]. The
EF test scores also are very poor at predicting impairment in a
variety of domains of major life activities, compared to EF
behavioural rating scales [125].
4.1.7. Burden of ADHD
The impairments associated with ADHD across the lifespan are
impressive. ADHD is associated with learning difficulties, school
dropout, underachievement at work [126], frequent job changes
[127], chronic fatigue [128], financial problems, gambling and
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increased mortality rates [131–133], relationship difficulties and
intimate partner violence [134,135], early onset of addiction
[136], teenage pregnancies and sexual transmitted diseases
[137,138], a two-fold increased smoking rate [139], an increased
number of suicide attempts and self-harm in adolescents
[140,141], and increased criminality [142,143]. Moreover, physical
disorders and ailments may become chronic due to forgetfulness,
health problems induced by a negative lifestyle, poor eating and
sleeping habits, and lack of health care follow-up [144–147].
ADHD has further been associated with auto-immune diseases
[148], obesity [149], and physical multi-morbidity. In one large
study, individuals with more than 4 diseases had over more than
3-fold higher odds of possible ADHD [146]. The risk of diabetes,
hypertension, cardiovascular disease and cancer, that are related
to obesity, may be increased as well. An additional burden on
family life may be the presence of one or more children with
ADHD, which happens frequently due to the high familial risks of
the disorder.
Clinicians should also be aware that high functioning adults with
ADHD may not present with a typical pattern of functional impair-
ments in their daily life. Adaptive or compensatory skills can develop
that mask the more overt behavioral problems related to ADHD [150].
Some may find work that is well suited to their symptom profile.
Furthermore, in ADHD neurocognitive performance and inattentive
symptoms are sensitive tothe salience of task activities [151,152]. Such
peoplewithADHDmayexcel incertainaspectsof theirlives,butstillbe
impaired in others, such as more routine and mundane tasks such as
paying bills, looking after the house, or developing stable social
relationships. Problems can include subjective distress from symp-
toms such as mental and physical restlessness, sleep problems, and
emotional instability; and the use of drugs such as cannabis or alcohol
to reduce these symptoms.
5. Prevalence of ADHD across the lifespan
In childhood, ADHD is among the most common psychiatric
disorders with a prevalence rate of 3–5 % [153]. For this age group,
well established diagnostic and treatment services are available
throughout most of Europe. In the last four decades, a large body of
evidence has accumulated, showing how in the majority of cases
ADHD is a lifespan disorder, persisting as either the full blown
disorder, or in ‘partial remission’ with persistence of some
symptoms and continued clinical and psychosocial impairments
[154–161]. The prevalence of ADHD in adults across twenty
countries was recently estimated at 2.8%, with a range between 1.4
- 3.6% [3]. ADHD was also found in a Dutch population study to
persist into old age (> 60 years) with a prevalence of 2.8–4.2%
depending on cut-off (6 or 4 current symptoms respectively), and
associated with impairment [162–166]. ADHD in older adults is
accompanied by increased rates of mood and anxiety symptoms,
general health problems, conflicts, divorce, loneliness, and a lower
income, showing a similar pattern of problems as in younger age
groups. Research exploring the needs for treatment of older adults
with ADHD has commenced, and the first treatment protocol of
older adults with ADHD has been published [167].
5.1. Sex issues
Sex differences in ADHD diagnosis are well documented, with girls
being less likely to be diagnosed, and sex ratios ranging between 1:5 to
1:9 [168]. Such discrepancy is less evident in epidemiological research
in children where the sex ratio is 1:3, suggesting under recognition of
ADHD in girls in the clinic. In both epidemiological and clinical studies
of adult ADHD the sex ratio is closer to 1:1 [169]. Several factors may
explain the sex disparity during the lifespan. Girls with ADHD mayhave less hyperactive/impulsive symptoms than boys; because of
higher disruptiveness, boys are more likely to be referred by parents
and teachers, whereas girls remain undiagnosed [170]. Missed
diagnosis may be due to a lack of knowledge and recognition of
ADHD in girls by health care professionals, and tothe presence of other
conditions: low self-esteem, anxiety as well affective disorders occur
frequently in females with ADHD, and it is possible that ADHD
symptoms may be mistakenly attributed to such comorbidities
[171,172]. Females with ADHD appear to develop better coping
strategies than males, and are better able to mask symptoms of ADHD
throughout childhood. However, this may no longer work well when
they face salient life challenges, such as leaving school, attending
college or university, commencing employment, managing intimate
relationships, and taking responsibility for their own life decisions
[173]. Different genetic liability between the sexes [174], as well
neuroendocrine factors affecting the dopaminergic system, such as
thyroid and estrogen hormones[172,175], have all been also suggested
to play a role in the masking of ADHD in girls and women. In addition,
girls and women with ADHD are less well studied than males.
Women with ADHD are particularly vulnerable to early
adversities, health and mental health problems compared to
controls [176]. A higher prevalence of insomnia, chronic pain,
suicidal ideation, generalized anxiety disorder, depressive disor-
ders, a greater vulnerability to nicotine dependence [176,177] and
an increased likelihood of risky sexual behaviors [138] has been
reported in women with ADHD in comparison with controls.
5.2. Transition of adolescents to adult mental health services
As two-thirds or more of children with ADHD continue to have
impairment into adulthood [178], many require the transition from
child to adult mental health services. However, transition between
services is generally difficult, placing youths with ADHD in an even
more vulnerable position [179]. Research shows that disruption of
care during transition adversely affects clinical outcome [180,181].
Clear recommendations have been formulated, mostly based on
clinical experience, to facilitate successful transition of patients
with ADHD from child to adult mental health services [1,182–185].
These are a) transition should ideally be completed by the age of 18
years, b) transition should be planned in advance by both child and
adult mental health services, c) young people with ADHD and their
parents should have sufficient information regarding the transition
process (e.g. psychoeducational material including available
services), d) both continued parental care and child’s growing
autonomy should be considered, e) if necessary a formal meeting
involving child and adult mental health services (with specific
knowledge on this age group) and patients and parents should be
considered. All these can help to prevent the drop-out of young
people with ADHD from services. However, the reality is quite
different, as indicated by two reviews [186,187]. Compared to other
diagnostic groups, youth with ADHD were significantly less likely
to be referred, they were more likely to refuse referral, and a
significant number remained in child services well beyond their
18th year. Studies also have found transition policy deficits
[186,188], suboptimal experience of transition when it does occur
[186,189], a dearth of adult ADHD services [190], and a lack of
expertise on ADHD amongst adult clinicians [3,191]. This suggests
there is an urgent need for a multifaceted approach combining
transition specific clinical guidelines, and funding for the training
the training of clinicians, to ensure that those in need of ongoing
intervention may successfully transition to adult services.
5.3. Late-onset ADHD?
Recent longitudinal studies have indicated that besides typical
childhood onset ADHD, with the full diagnostic criteria being met
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the full diagnostic criteria beyond this age [104,189,190]. These
findings have proven controversial due to severe methodological
limitations [192,193], however the large majority of later onset cases
appear to meet the DSM-5 age of onset criteria of several symptoms by
the age of 12 [113]. Late onset of symptoms was evaluated in the
control arm of the long-term follow-up of the Multimodal Treatment
study of ADHD (MTA). In most cases, other factors were present that
could discount the late onset of ADHD symptoms and exclude the
diagnosis of ADHD [194], such as symptoms representing non-
impairing cognitive fluctuations, a comorbid disorder, or the cognitive
effects of substance use [192]. However, there remained a very small
sample of adolescent onset cases. Another population cohort study
found that the majority of those with apparent late-onset ADHD had
high ADHD scores at least one point in childhood, suggesting that they
may have been misclassified on the basis of their score at age 12 years
[195]. These cases with high score before the age of 12 years might not
have met full criteria before the age of 12 years, but would meet the
current DSM-5 criteria for several symptoms in childhood. One
conclusionisthatcliniciansshouldbeawarethatsubthresholdcasesof
ADHDduringchildhoodmightgoontomeetthefull diagnosticcriteria
as older adolescents. Clinicians should take care to fully assess
impairment, psychiatric history, and substance use when diagnosing
and treating cases with apparent later-onset ADHD [192].
6. Screening and diagnostic assessment
6.1. Screening
Several screening tools are available for ADHD in adults. The
validated tool recognized by the World Health Organization (WHO)
and updated for DSM-5 criteria is the Adult ADHD Self report
Rating Scale (ASRS). This revised ASRS was studied in managed
care, the general population and in a clinical group. The sensitivity
was 91.4%; specificity 96.0%; AUC, 0.94; PPV, 67.3% [196]. The
previous version of the ASRS has been translated into many
languages (see http://www.hcp.med.harvard.edu/ncs/asrs.php).
The Wender Utah Rating Scale assesses besides ADHD a broader
spectrum of symptoms that often accompany ADHD or are
comorbid. Several other scales that ask about the 18 items as
defined in the DSM-5 to classify ADHD are available, see Table 2.
A key question is who should be screened for ADHD. In general,
since the hallmark of adult ADHD is a chronic trait-like condition
that emerges out of childhood or early adolescence, anyone
presenting with such a clinical picture should be screened [2]. This
should include those with chronic histories of inattentive, restless
or impulsive behaviors, as well as those with emotional instability.
Targeted groups where rates of ADHD are significantly increased
and should therefore be screened include family members of
people with ADHD, and those with a history of behavioral
problems, any chronic mental health disorder including anxiety,Table 2
Open access Scales and Interviews for Diagnostic Assessment of ADHD in adulthood.
Scalesa
Adult ADHD Self-Report Scale Developed by WHO; 6-item ve
DSM-5 (ASRS), in many langua
https://www.ncbi.nlm.nih.gov/
Wender Utah Rating Scale https://www.thecalculator.co/h
Diagnostic Interviewsb
DIVA-5 Structured Diagnostic Intervie
ACE+ Semi-structured Interview for
a Other scales without open access are: Conners Adult ADHD Rating Scale (CAARS), 
b Other interviews without open access are: Conners Adult ADHD Diagnostic Intervidepression, cyclothymia, personality disorder, bipolar disorder,
substance use disorders, those with multiple physical diseases
[146], and those within the criminal justice system [197].
6.2. Diagnostic assessment
For diagnostic assessment, the use of a semi-structured
diagnostic interview is advised, such as the Diagnostic Interview
for ADHD in adults, second edition (DIVA 2.0) [198], based on the
DSM-IV-TR criteria. DIVA 2.0 is available online without charge,
currently in 19 languages (www.divacenter.eu). The Conner’s Adult
ADHD Diagnostic Interview for DSM-IV (CAADID) has been
validated in English and Spanish [199]. DIVA 2.0 has been validated
in two European populations [81,199], and is increasingly used in
international research. A DIVA 2.0 app is available in the App and
Google Play stores. The update of DIVA 2.0 for DSM-5 criteria into
‘DIVA-5’ in all languages is ongoing. DIVA-5-ID, for people with
Intellectual Disability (ID) and Young DIVA, for children and
adolescents, are new versions of DIVA-5. An alternative is ACE+
(http://www.psychology-services.uk.com/resources.htm), a semi-
structured diagnostic interview to assess ADHD in adults (>16
years). ACE + assesses the core symptoms of ADHD in both
adulthood and childhood, the extent to which they impair
functioning, and the presence of co-existing conditions. ACE + is
currently online available in 7 languages, with more translations
underway. For these and other diagnostic tools, see Table 2.
6.3. The assessment process of ADHD and comorbidity
Diagnosis ofADHD is based on a careful and systematic assessment
of a lifetime history of symptoms and impairment. Central to this
processistheassessmentofchildhood-onsetandcurrentsymptomsof
ADHD, and the presence of symptoms and impairment in at least two
domains(school,work,home, interpersonalcontacts).Forthis lifetime
assessment, collateral information from family members and spouse
are useful. It is important to take a full medical history of psychiatric
and somatic conditions, as well as a family history of psychiatric and
neurological problems. High intelligence should be taken into account
as a potential moderator in the diagnostic assessment, as ADHD is
underdiagnosed in patients with high intelligence because they use
more compensatory strategies [200]. Clinicians should also be aware
that high functioning adults with ADHDmaynotpresentwith atypical
pattern of functional impairments in their daily life. Adaptive or
compensatory skills can develop that mask the more overt behavioral
problems related to ADHD [150]. Some may find work that is well
suitedtotheirsymptomprofile.Furthermore, inADHDneurocognitive
performance and inattentive symptoms are sensitive to the salience of
task activities [151,152]. Such people with ADHD may excel in certain
aspects of their lives, but still be impaired in others, such as more
routine and mundane tasks such as paying bills, looking after the
house, or developing stable social relationships. Problems can includersion, based on
ges
pmc/articles/PMC5470397/
ealth/Wender-Utah-ADHD-Rating-Scale-Calculator-858.html
w for ADHD in adults; according to DSM-5; in 19 languages www.divacenter.eu
 ADHD in adults https://www.psychology-services.uk.com/adhd.htm
and the Adult ADHD Investigator Rating Scale (AISRS).
ew (CAADID), Adult ADHD Clinical Diagnostic Scale (ACDS).
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restlessness, sleep problems, and emotional instability; and the use of
drugs such as cannabis or alcohol to reduce these symptoms.
Adult diagnoses may be missed in clinical practice due to lack
of knowledge about ADHD in adulthood among practitioners and
due to the high frequency of comorbid psychiatric conditions
[201]. The lifetime co-morbidity rate is 60–80%. Having three or
more disorders was associated with a ten-fold increase of the
chance of having ADHD in a population study in 20 countries [3].
Before treatment start, all comorbidities must be established so
that the best order of treatment can be determined together with
the patient. In the study by Fayyad et al, data on ADHD and
comorbidities was collected on 26,744 respondents [202]. In
adults with ADHD having one comorbidity was found in 23% of
cases, two in 14% of cases and three in 14% of cases. Rates were
particulary high for any mood disorder (22%), any anxiety
disorder (34%), substance use disorders (11%) and any behavioural
disorder (15%).
Psychiatric comorbidity is thus a clinically important dimen-
sion of ADHD heterogeneity and a factor that contributes to the
persistence of ADHD in adulthood [203,204]. It is important for the
diagnosis of ADHD, as well as the correct targeting of treatments, to
identify mood, anxiety, eating, sleep, somatic and substance use
disorders, in addition to personality, tic and autistic spectrum
disorders [205]. Because adults with ADHD often exhibit low self-
esteem, low mood, mood lability and irritability, these symptoms
may sometimes be confused with dysthymia, cyclothymia, bipolar
disorder or borderline personality disorder. Furthermore, daily
mood changes in ADHD are very common, and represent a poorly
regulated but essentially normal range of moods, rather than the
more severe extremes of depression and elation as seen in bipolar
disorder. It has been argued that chronic mood instability should
be considered part of the core syndrome of ADHD [206,207]. ADHD
and borderline personality disorder share symptoms of impulsivi-
ty, mood instability, anger outbursts and feelings of boredom
[158,208,209]. In the ADHD patient, impulsivity and anger are
usually short-lived and thoughtless rather than driven. Conflicts in
relationships, suicidal preoccupation, self-mutilation, identity
disturbances and feelings of abandonment are usually less intense
than in borderline personality disorder. However, the differences
may not be clear-cut because these symptoms are chronic and
trait-like in both conditions [210].
ADHD in children is also associated with increased rates of
neurodevelopmental disorders like autism spectrum disorder,
dyslexia and impaired motor coordination which are thought to
arise from overlapping genetic influences [211]. Such neuro-
developmental comorbidities are less well studied in adults, but
they are commonly observed in clinical practice and may lead to
continued impairments. As the order of treatment will depend on
the presence and severity of comorbidities, evaluation of comorbid
disorders is a key component of the ADHD assessment process,
using appropriate clinical diagnostic approaches.
6.4. ADHD and criminality
The prevalence of ADHD is increased in forensic populations
compared to the general population [212], and the risk of
criminality is increased in individuals with ADHD, especially in
those with comorbid oppositional defiant disorder, conduct
disorder, substance misuse and antisocial personality disorder
[213]. A meta-analysis comprising 42 studies from 15 countries
reported a 5-fold increased prevalence of ADHD in youth prison
populations (30%) and a 10-fold increased prevalence in adult
prison populations (26%) as compared to the general population
[214]. When using diagnostic clinical interviews, the estimated
ADHD prevalence in prisoners was 25.5%, without significantdifferences for gender and age [214]. Further, inmates with ADHD
compared to those without are reported to have higher rates of
psychiatric morbidity including substance misuse, an earlier onset
of offending, more violent offences, criminal recidivism and more
frequent and severe institutional aggression [215,216].
7. Treatment
7.1. Effective treatments
The treatment of adults with ADHD should follow a multimodal
and multidisciplinary approach, which includes psychoeducation,
pharmacotherapy, cognitive behavior therapy (CBT) and coaching
for ADHD, which are all discussed in this article.
Ideally, the treatment plan also involves the adult’s partner,
family or close relationships, and in some cases systemic (family)
therapy may be required when gross disruption to family
relationships and functioning is present.
7.2. Treatment focus in comorbid ADHD
In the most recent report of 20 nationally or regionally
representative World Mental Health surveys, data on ADHD and
comorbidities was collected on 26,744 respondents [202]. In adults
with ADHD having one comorbidity was found in 23% of cases, two
in 14% of case and three in 14% of cases. Rates were particulary high
for any mood disorder (22%), any anxiety disorder (34%), substance
use disorders (11%) and any behavioural disorder (15%). Treatment
of ADHD is therefore most often in the context of co-occuring
disorders.
Before treatment starts, all comorbidities must be established
so that the best order of treatment can be determined together
with the patient. In general, the most severe disorder is prioritized.
For instance, psychosis, bipolar disorder, substance abuse, severe
depression and severe anxiety are usually treated first. Milder
mood or anxiety disorders, and emotional instability, may respond
to treatment of ADHD and can be treated at the same time as
ADHD. Drug and alcohol abuse should be stabilized but can be
treated at the same time as ADHD.
7.3. Psychoeducation on ADHD
According to consensus based on good clinical practice and the
need to work on an informed consent basis within a multimodal
treatment approach, psychoeducation should be the first step as a
standard of care [217]. First evidence from an open trial and a
randomized clinical trial shows, that patients and significant
others who attend a structured psychoeducation program increase
their knowledge about ADHD, and improve the quality of their
relationships and psychological well-being [218,219].
7.4. Pharmacotherapy for ADHD
7.4.1. Introduction on pharmacotherapy
In the first European Consensus Statement [1] psychostimu-
lants (methylphenidate and dexamphetamine) were recom-
mended as the first-line pharmacotherapy for adult ADHD
[1,184,220], as they exert moderate-to-high clinical effects, with
average effects higher than atomoxetine (ATX) and other non-
stimulant medications [2]. There were, however, no head-to-head
studies providing robust comparative analysis of efficacy differ-
ences [221]. Across most of Europe, lisdexamfetamine (LDX) has
been introduced as a slow release formulation of dexamphet-
amine. The recent systematic review and network meta-analysis
on the comparative efficacy and tolerability of medications for
ADHD in children, adolescents and adults by Sam Cortese et al.
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and adolescents is methylphenidate, and amphetamines in adults
[222]. In fact in adults, amphetamines were not only the most
efficacious compounds, as rated by clinicians and by self-report,
but also as well tolerated as methylphenidate and the only
compounds with better acceptability than placebo.
7.4.2. Licensing
Licensing of ADHD medications for adults is more diverse than
in 2009 [1], reflecting greater understanding of ADHD, and efforts
to market ADHD medications in Europe. In Denmark, Ireland,
Norway, Sweden, Switzerland, the Netherlands and the United
Kingdom, most ADHD medications can be prescribed, either with a
full license (e.g. Medikinet1, Strattera1, Elvanse1) or transitional
licenses (e.g. Concerta XL1) and off-label prescribing is endorsed
by national guidelines and formularies. Dexmethylphenidate
(Focalin XR1) is licensed in Switzerland only. In other countries,
only a limited selection of medications is available for funding by
the state sector, but off label prescribing is possible. In another
group of countries (e.g. Greece, Slovenia, Poland), only very few
ADHD medications are available, with off-label prescribing mostly
in the private sector. The European Network on Adult ADHD
(ENAA) and the Neurodevelopmental Disorders Across the Lifespan
(NDAL) section at EPA strongly recommend that evidence-based
treatments for adult ADHD are made more available and licensed
across European countries.
7.4.3. Efficacy and adverse effects of stimulants
Meta-analyses of randomized controlled trials (RCTs) demon-
strate the efficacy of stimulants and ATX in the reduction of ADHD
symptoms in adults [223–227]. Standardized mean differences
(SMDs) range from 0.4 to 0.7, with stimulants showing greater
efficacy than ATX [224]. The longest RCT in adults still found
significant effects of MPH after one year [228]. National registry
data also suggest long term benefits. Although these studies are not
definitive due to lack of randomization and controls, they
demonstrate ‘real-world’ societal benefits associated with the
use of ADHD medications. These studies show that during periods
of receiving medications for ADHD there are marked reductions in
transport accidents and mortality rates [132,229], criminal
convictions [230], suicidal behavior [231], violent reoffending
[230], depression [232] and substance misuse [233]. Similar
analyses with antidepressants find no effects, suggesting the
effects are specific to ADHD medications.
A 2011 meta-analysis [225] revealed that MPH (mean dose
41.2–82 mg/day) exerted a moderate effect on ADHD symptoms,
with large effects observed at doses of >77.4 mg/day. Immediate
release (IR) MPH has a short duration of action of maximum 4 h.
Due to difficulties with compliance when needing to take
medication up to several times a day, long-acting MPH prepara-
tions have been developed, with durations of action ranging
between 6–12 h.
The recommended dose range of Immediate Release dexam-
phetamine (IR) is 5–60 mg/day [220]. Lisdexamfetamine (LDX) has
a slow release profile giving the drug a relatively low abuse profile
[234]. LDX is taken once daily with a mode of action of up to 14 h
[235]. Three RCTs in adults indicate moderate to large effects on
ADHD symptoms [236–238] (SMD = 0.97) [239], comparable to
MPH. The safety and tolerability profile is similar to other
stimulants [240,241].
The main adverse effects of stimulants are increased heart rate
and blood pressure, and reduced appetite and sleep [242–245].
Heart rate, blood pressure, sleep problems and weight are
therefore assessed before, and monitored at least twice a year
during treatment. Serious cardiac complications are rare
[243,246,247] with reported risks for myocardial infarction,sudden cardiac death, ventricular arrhythmias or stroke no more
than 0.2-0.4% higher in one study [248]. MPH might trigger
arrhythmias in patients with congenital heart diseases [249]. The
consensus is caution in patients with known cardiac defects, but
risks are small.
7.4.4. Atomoxetine
ATX yields moderate efficacy in reducing ADHD symptoms
(SMD: –0.33 to –0.40) [227]. Onset of action is 1–2 weeks, and full
effects may take up to 6 months to develop [250]. If rapid onset of
effect is not essential, ATX may be a good choice for high risk
patients who need stable control of ADHD symptoms [251].
The use of ATX as first line in drug abusers continues to be
debated with other experts preferring stimulants due to rapid
onset and potentially greater effects [252]. Although in the past
there were concerns that stimulants may increase the risk of
substance use disorders (SUD), there is now a wealth of data
demonstrating reductions in SUD during periods of treatment of
ADHD with stimulants [233,253].
ATX may be a good choice with co-occurring anxiety that might
be exacerbated by stimulants, as a RCT of adults with comorbid
ADHD and social anxiety disorder found improvements in both
ADHD and social anxiety [254]. ATX does not appear to be effective
in the treatment of comorbid depression in adolescents [255].
7.4.5. Guanfacine and clonidine
In Europe, guanfacine extended-release (GXR), an alfa-2
adrenergic agonist, is licensed for the treatment of children and
adolescents with ADHD for whom stimulants are not suitable, not
tolerated or where shown to be ineffective [256,257], whereas in
the US, IR guanfacine is approved for use in children and adults
with ADHD (both as monotherapy and in combination with
stimulants). Notably, there are currently no RCTs in adult patients
to support the use of GXR in this age group, only a study using GXR
or placebo as an adjunct to stimulant treatment that had
insufficient effect. Both treatments did not differ in efficacy [258].
Extended-release (ER) clonidine is approved in the US for
treatment of ADHD in 6–17- year olds as monotherapy or an
adjunct to stimulants. There are RCTs on both ER clonidine
[259,260] and IR clonidine [261,262] in children and adolescents
with ADHD, but no equivalent studies in adults.
7.4.6. Bupropion
There are conflicting findings for bupropion from a small
number of adult studies. Positive results were reported with higher
doses (400–450 mg per day) [263,264]. Due to a limited evidence
base, bupropion use should be restricted to cases who do not
tolerate other ADHD medications.
7.4.7. Other medications
Selective noradrenaline reuptake inhibitors such as reboxetine
may be an alternative to ATX [265,266]. There is limited evidence
for tricyclic antidepressants [267,268]. Selective serotonin reup-
take inhibitors (SSRIs) are not effective for the treatment of ADHD
[229,230,269]. Modafinil, a wakefulness-promoting agent used in
the treatment of narcolepsy, has not been demonstrated as an
effective treatment for adult ADHD in a phase 3 trial that had high
rates of side effects (86%) and drop-out (47%) possibly resulting
from excessive doses (210–510 mg/day) [270].
7.4.8. Long-term safety concerns
Currently there is no evidence of significant long-term risks
using stimulants. Tomography scans find higher striatal dopamine
transporter availability in ADHD patients treated with stimulants
[271]. The clinical implications of this up-regulation are not clear.
Potential toxicity on heart valves of medications with an agonist
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MPH and guanfacine. Some argue that echocardiography should be
routinely performed prior to treatment with potential valvulo-
pathic drugs [273]. This risk is not however established, and we
and others do not recommend routine echocardiograms
[184,252,274], except in older adults (> age 50) [167].
7.4.9. Combined psychopharmacology
The high rate of psychiatric comorbidity in adult ADHD
frequently necessitates combined psychopharmacology [275].
Accordingly, the risk of possible drug-drug interactions when
treating adults with ADHD must be considered. These include the
following:
– Monoamine oxidase inhibitors are generally contraindicated due
to the risk of hypertensive crisis.
– Although MPH is mainly metabolized in the liver, drug
interactions via CYP enzymes are uncommon. Amphetamines,
however, are metabolized primarily via the CYP 2D6 enzyme
system making drug interactions possible (with inhibitors or
inducers of this enzyme system, e.g. fluoxetine and paroxetine)
[276].
– Treatment with medications that act on the noradrenaline
system, including certain antidepressants (e.g. duloxetine,
venlafaxine), will have an additive effect and may increase the
risk of hypertension and other adverse cardiovascular events.
– Due to its metabolism by the CYP 2D6 enzyme system, ATX levels
can increase in combination with enzyme-inhibiting SSRIs (e.g.
fluoxetine and paroxetine) [277].
7.5. Considerations when treating special groups with
pharmacotherapy
7.5.1. ADHD with comorbid bipolar disorder
A pharmaco-epidemiological study found that MPH mono-
therapy in patients with bipolar disorder increased the risk of
switch to a manic episode (hazard ratio 6.7). However, when
combined with a mood stabilizer, MPH reduced the risk of mania
(hazard ratio 0.6) [278]. This supports the current recommenda-
tion to treat ADHD in bipolar disorder patients with stimulants, so
long as they are also taking mood stabilizers.
7.5.2. ADHD with comorbid substance use
Meta-analysis of RCTs in adults found that most ADHD
medications reduce the core symptom severity of ADHD, but have
limited effect on comorbid substance use [279]. However, a large
Danish Registry study showed a decrease of substance use in ADHD
patients when using MPH [280]. Recent RCTs using higher doses of
ER Mixed Amphetamine Salts (Adderall XR1) or OROS MPH
(Concerta1), combined with CBT found better effects on both
ADHD and substance use, compared to studies using lower dosages
[281,282]. The relevance of higher doses is supported by a
pharmaco-epidemiological study from Sweden showing that
higher MPH dose was associated with long-term treatment
adherence in patients with ADHD and substance use disorders
(SUD) [283]. Immediate-release stimulants should be avoided in
patients with ADHD and SUD, whereas OROS-MPH and LDX have
lower abuse potential [284]. Further recommendations for treating
comorbid substance use disorders can be found in Bolea-Alamanac
et al. [184], and in the recently published international Consensus
Statement on diagnosis and treatment of substance use disorders
with comorbid ADHD [285]. This Consensus Statement mentions
that the use of stimulant treatment for ADHD does not precipitate
the onset of SUD in adults without previous SUD [286]; also that in
SUD patients, treatment of ADHD can be useful to reduce ADHDsymptoms without worsening the SUD, and should not be avoided
[287].
7.5.3. Cognitive enhancement in students
Another group where screening for ADHD is appropriate is the
student population. This is because we know that ADHD specially
interferes with educational attainment. Further, this has been
highlighted be the finding that genetic risks for ADHD overlap with
those for educational outcomes [28]. Student groups with
particularly high rates of ADHD include those presenting with
specific learning difficulties [288] and mental health problems
[202]. Related to this, there are concerns, particularly in countries
with a higher rate of stimulant prescriptions, that students may
seek the diagnosis of ADHD to receive stimulants for cognitive
enhancement. Some studies show that although most students use
their ADHD medication as prescribed, misuse and diversion is not
uncommon [289]. Care must therefore be taken to ensure that
students are diagnosed and treated for ADHD when appropriate,
while minimising risks of diversion.
7.5.4. Pregnancy and breastfeeding
There is only limited information on the effects of ADHD
medication on the fetus and new-born [290]. As suggested by
population-based studies, MPH or amphetamine exposure during
pregnancy is not related to higher rates of any congenital
malformations [291–293]. For cardiac malformations, MPH use
was associated with a small increased risk (RR 1.28 (95% CI, 0.94–
1.74), where amphetamines were not. There is some evidence
suggesting that treatment with MPH or ATX might increase the risk
of miscarriage [294,295], although there were several confounding
factors such as younger age and social disadvantage, that could
explain the association [296]. Another study found that the use of
stimulant medication during pregnancy is associated with
miscarriage to the same degree as having ADHD itself [295], these
findings need further investigation. Potential adverse effects on the
fetus from intra placental exposure to medication in pregnancy
should be considered against the possible adverse effects of
interrupting treatment abruptly in women with ADHD
[184,297,298]. Each case should be assessed individually taking
into account possible risks of both treating and interrupting
treatment.
Amphetamines may be given preference over other medica-
tions. Some authors do not consider Atomoxetine because of lack of
safety data [299,300]. MPH seems to be safe during breastfeeding.
The amounts of medication excreted in breast milk, and consumed
by the infant, are very small (with the Relative Infant Dose (RID) (<
1%) [290,299], and no drug-related side effects have been were
reported. The impact of ATX, guanfacine, and clonidine on
breastfeeding-related outcomes is largely unknown [301–303],
and they are not recommended [299].
Until now no adverse reactions were reported among infants of
mothers receiving LDX or dexamphetamine (RID: 4–10.6%). There
are some preliminary reports suggesting that dexamphetamine
treatment may lead to a suppression of prolactin secretion in
postpartum women, though with unclear clinical implications
[304]. Bupropion was found to produce low levels in milk,
suggesting relative safety. Of note, there are two known cases of
seizures developed by children breastfed by women receiving
bupropion [305].
7.5.5. ADHD and sleep problems
In the majority of cases, ADHD in children and adults is
associated with a circadian rhythm disorder with delayed sleep
onset [306–308]. Meta-analysis of nine studies investigating the
effects of stimulant medication on sleep in children and
adolescents found that stimulants can lead to longer sleep latency,
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findings have been reported in adults [310]. Careful titration of
stimulants and psychoeducation around sleep optimization can
improve the quality of sleep, possibly due to improved daytime
structure, the maintenance of regular physical activity and
improved mood [198,309,311]. In children with ADHD and chronic
insomnia, melatonin has been shown to advance the sleep onset,
and increase sleep duration [312]. A trial targeting insomnia in
adults with ADHD is ongoing, and clinical experience points in the
same direction of possible efficacy of treatment with melatonin at
night, and also of light therapy in the morning [308]. Treatment of
insomnia should always start with sleep hygiene education and
optimizing the stimulant or non-stimulant treatment of ADHD
[311]. A low dose of IR MPH (usually 5 mg) taken at night time can
reduce ceaseless mental activity to a degree that allows sleep in
some cases.
7.6. Cognitive behavior therapy (CBT) and coaching for ADHD
Although pharmacological treatment of ADHD is very effective,
many patients continue to experience significant symptoms and
functional impairment in daily living. Empirical evidence from
numerous uncontrolled studies, more than ten randomized
controlled trials (RCTs) and a meta-analysis has shown that in
group or individual settings, cognitive behavioral therapy (CBT)
reduces ADHD-core symptoms, associated symptoms such as
emotion dysregulation, anxiety and depression, and functional
impairments across different areas of daily living in adults
[228,313–315]. CBT is best used within a multi-modal treatment
approach and as an adjunct to medication as current research does
not fully support the efficacy of CBT as a sole treatment for adult
ADHD [274,316–318]. Most controlled studies have been con-
ducted in patients taking ADHD medication and demonstrate an
additional significant treatment effect [313,318–322]. The largest
controlled multi-center CBT-study to date has demonstrated that
psychological interventions result in better outcomes when
combined with MPH as compared to psychological interventions
in unmedicated patients [228]. In a systematic review of 51
pharmacological and non-pharmacological interventions [316],
the highest proportion of improved outcomes (83%) was for
patients receiving combination treatment. However, not all adults
with ADHD desire or tolerate pharmacological treatment. In these
cases CBT may be the best option.
Across all studies there are some consistent characteristics of
CBT treatment, both in form and content. All approaches are highly
structured. Most are manualized, and establish psychoeducation as
the first step. Most programs are skills-based and focus on
organizational and time management skills, emotional regulation/
control, problem solving skills, prosocial competence and strate-
gies to improve attention and impulsivity management. In addition
to behavioral interventions that require patients to try out and
rehearse in daily life techniques suggested in the therapy session,
programs include cognitive strategies, such as the identification of
negative automatic thoughts, methods to address ‘thinking errors’
and the introduction of cognitive restructuring techniques [323].
There is emerging evidence that cognitive distortions and
dysfunctional cognitive schemes related to a biographic accumu-
lation of negative experiences associated with ADHD-symptoms
contribute to negative functional outcomes and lead to avoidance
behavior, failure-orientation, reduced self-efficacy, procrastina-
tion, depressive symptoms and anxiety [324–326]. Furthermore,
most programs highlight the importance of including significant
others in the treatment process to reduce dysfunctional inter-
actions and stigmatization associated with ADHD symptoms.
Coaching or mentoring is a derivative of the cognitive
behavioral paradigm involving the development of a collaborativementoring partnership. Coaching aims to provide structure,
support and feedback for building life skills and changing negative
outcomes related to ADHD in daily living [217,327,328]. However,
there is no standard methodology and the coaching process varies
considerably, including face-to-face contact, telephone calls and/
or email contact. To date, there are no controlled studies assessing
the efficacy of coaching as a therapeutic means in the treatment of
adults with ADHD. Nevertheless there is some preliminary
support for positive outcomes from uncontrolled studies
[327,328]. Similarly there is some support for the effectiveness
of mindfulness based cognitive therapy (MBCT) for adults with
ADHD [329–331].
8. Cost and cost effectiveness
Because of the broad impact of ADHD on general functioning,
the disorder is likely to have serious economic implications for
children, families, and society. The studies which calculate costs
however are so far limited as they typically examine only one
aspect of the costs, for example “from the perspective of a major
German health insurance fund” [332]. Particularly for adults with
ADHD, estimates should include not only direct costs (the costs of
labor, supplies, and equipment to provide direct patient care
services) but also indirect costs (mainly related to the loss of
productivity) such as costs to family, costs due to impairment in
employment, costs due to accidents [333], smoking and substance
misuse, and costs due to involvement with the criminal justice
system.
Direct costs have been examined [334–336], but are heavily
depending on the healthcare system from which they are derived
and the type of pathway/care package provided. These estimates
therefore, although potentially useful for comparisons between
disorders within the same healthcare system, should not be
generalized to different contexts. The most comprehensive
approach to calculate the total costs of ADHD in the Danish
Psychiatric Central Register, showed that there is an economic
burden of ADHD which is considerable and falls both on the
individual and the state [337].
Apart from the costs (either direct or indirect) of ADHD, there is
also the question of cost benefit for treating ADHD. This first asks
whether a treatment of a disorder is worthwhile when compared
against alternatives in terms of allocation of healthcare funds, and
second which ADHD intervention brings the most benefit at the
lowest cost. For the former, an argument can be made that adult
ADHD is a condition which is cost effective to treat from the
societal perspective because of the efficacy and relatively low cost
of the medicines used for its treatment [224,338]. For the latter,
among children and adolescents with ADHD, there is consistent
evidence [339–343] that pharmacotherapies are cost effective
compared with no treatment or behavioral therapy [344].
Unfortunately there is insufficient research to conclude the same
for adults with ADHD (Table 3).
9. Stigma surrounding ADHD
Substantial stigmatization and myths continue to surround
ADHD [345]. A recent study on negative coverage of ADHD and
autism in Flemish newspapers found a 2-fold more negative than
neutral or positive coverage of ADHD than of autism [346]. Stigma
arises from lack of awareness, of prejudice about symptom etiology
(e.g. poor parenting, lack of moral), incompetence (e.g. laziness)
and perceived dangerousness (e.g. unpredictable and potentially
violent behavior) [347]. Other variables contributing to stigma are
doubts about the validity and reliability of an ADHD diagnosis,
along with age, gender, ethnicity and the public's skepticism
toward ADHD medication. Also, the restricted regulatory status for
Table 3
Summary of key points.
Neurobiological and
environmental
background
High heritability (60-80%), environmental risk factors and their interaction, are involved in the majority of ADHD cases.
Abnormalities in grey matter, cortical thickness and white matter microstructure have been shown in ADHD compared to controls, indicating
that structural deficits in ADHD involve interconnections among large scale brain networks.
Functional neuroimaging shows dysfunctions in several domain-specific fronto-striatal and fronto-cerebellar neural networks, as well as an
enhanced activation of default mode regions.
These findings, as well as the effectiveness of pharmacological treatments with dopamine agonists, support the neurobiological underpinnings
of ADHD.
Diagnosis The clinical diagnosis of ADHD depends on self-report during a structured diagnostic interview, whenever possible with collateral information
about lifetime symptoms and impairment. It cannot be established using solely neuropsychological tests.
Recent research shows that besides inattention, hyperactivity and impulsivity, emotional dysregulation and excessive mind wandering are
common symptoms associated with ADHD in adults.
The underdiagnosis of girls and women with ADHD may be due to a different expression of symptoms and comorbidities, to referral bias, and to
interaction of hormones with the dopaminergic system. Further research is needed.
The concept of late-onset ADHD refers to an age of onset after 12 years, and needs further study concerning the overlap and differences with
childhood onset ADHD.
High rates of psychiatric comorbidity, physical multi-morbidity, increased mortality and suicide rates, and criminality may ‘mask’ the
underlying ADHD condition.
Stigma leads to misconceptions about ADHD and underdiagnosis.
DSM-5 criteria Main changes in the DSM-5 criteria for ADHD are:
ADHD is placed in the chapter of Neurodevelopmental Disorders
The age of onset of symptoms is before age 12, instead of age 7
The cut off for current symptoms in adults is 5/9 instead of 6/9
A diagnosis of ADHD can now be combined with Autism Spectrum Disorder (ASD)
Prevalence The mean prevalence of ADHD in adults across 20 countries is estimated at 2.8%. In people above age 60, a similar prevalence rate has been
found.
The prevalence of ADHD in prisons is 25%, a 10-fold increase compared to the general population.
Transition Two-thirds of children with ADHD continue to have ADHD symptoms associated with impairments in adulthood, therefore adjustments in the
health care system to support the transition from child to adult services are needed.
Treatment Psychoeducation for adults with ADHD and their significant others is recommended as a first treatment step.
Stimulants are the treatment of choice for adults with ADHD. Long-lasting, extended release formulations are preferred for reasons of
adherence to treatment, for the protection against abuse, to avoid rebound symptoms, for safer driving, and to provide cover throughout the
day without the need for multiple dosing.
Licensing of stimulants for adult ADHD is urgently needed in European countries and beyond.
The non-stimulant atomoxetine is recommended as a second line treatment. There is limited evidence in adults for guanfacine, bupropion,
tricyclic antidepressants and reboxetine in controlled studies.
Cognitive Behavior Therapy reduces ADHD-core symptoms, associated symptoms such as emotion dysregulation, anxiety and depression, and
functional impairments across different areas of daily living in adults. CBT is best used within a multi-modal treatment approach and as an
adjunct to medication, as research does not fully support the efficacy of CBT as a sole treatment for adult ADHD.
Pharmacological
treatment
of special groups
In patients with ADHD and substance use disorder, to be effective, treatment with stimulants may use higher dosages than normal.
In patients with ADHD and bipolar disorder, the combined approach of a mood stabilizer with a stimulant has been shown to treat both
disorders effectively without inducing (hypo)manic states.
During pregnancy stimulants are not advised, though large cohort data showed no increased risk for congenital malformations using stimulants
during the first trimester. The risk for cardiac malformations using MPH however was slightly increased, while this was not the case for
amphetamines.
Research on the wishes of older people with ADHD regarding treatment, and trials on the safety and efficacy of medicines are needed.
Based on data from large cohort studies, following treatment, the negative outcomes associated with ADHD significantly diminish, i.e. traffic
accidents, mortality, criminality, depression and suicide, and substance abuse.
Costs The economic burden of ADHD is considerable and falls both on the individual and the state. Pharmacotherapy in children is cost effective
compared to no treatment and behavioral therapy, but data in adults are still lacking.
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mental health profession and the media. Public stigmatization of
ADHD, and the following self-stigma and courtesy stigma are
underestimated risk factors for treatment adherence, treatment
efficacy, symptom aggravation, life satisfaction, and mental well-
being of individuals affected by ADHD [348].
Self-stigma has been studied in children and adolescents and is
characterized by a sense of feeling different from peers, and
negative self-evaluation as a consequence of that perception.
However, some young people were prepared to challenge the
stigma by self-disclosure and openness about their condition
[349]. Lower stigma in teachers towards adult ADHD seems to
relate to greater knowledge about the condition [350]. Among
general practitioners (GPs) from the UK, Europe and Australia,
there is mixed and often unhelpful attitudes regarding the validity
of ADHD as a construct, the role of medication and how parenting
contributes to the presentation [351]. A paucity of training wasidentified, alongside a reluctance of GPs to become involved in
shared care practice. If access to services is to be improved for
people with ADHD, there needs to be a focused and collaborative
approach to training [351].
9.1. Combatting stigma
Disclosure of mental health problems can be a challenge [352],
but an increasing number of celebrities have cast aside stigma by
revealing they had ADHD and, in some cases, have been
pharmacologically treated for many years (https://www.additu-
demag.com/successful-people-with-adhd-learning-disabilities/).
This is of course supportive for patients but it is strongly
recommended that psychoeducation about ADHD should be
included in anti-stigma programs [347]. Of note, adult ADHD is
rarely included in college programs for medical and psychology
students, or in the training of professionals working in adult
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underdiagnosis and undertreatment among professionals [2,3].
Psychoeducation programs therefore need to target all clinical
disciplines at all stages of professional development (e.g. from
students through to primary and secondary care physicians,
psychologists and nurses) to ensure that appropriate early
recognition, diagnosis and treatment is provided.
Internationally recognized guidelines are available on the
assessment, treatment and management of adults with ADHD,
as well as the development and provision of clinical services
[182,184,274,353]. The current lack of licensed indications for the
use of stimulants in adults in most European countries (but not in
the US or Canada) is not supported by available data, but rather
results from the outdated focus that ADHD is a ‘child disorder’,
caution from regulators regarding potential cardiovascular side
effects, and commercial manipulation by the pharmaceutical
industry. In Europe, this situation may change in the coming years
as formulations of methylphenidate and dexamphetamine are
being put forward for registration.
Stigma prevents patients to ask for help and increases their
suffering and impairment. Hence the successful management of
ADHD by prescribers will include an awareness of the potential
stigma that may be perceived by the patient and its consequences
on treatment initiation and maintenance. The only way to reduce
stigma surrounding ADHD is community, health and education
systems in Europe and beyond working together by education of
professionals and the public, and by a unified licensing of
medications for ADHD in adults.
10. Conclusions
This consensus statement reflects agreement on the state of
ADHD, but by definition it is provisional. It does not negate the
ongoing scientific debate in the field and the different opinions and
hypotheses about adult ADHD among experts. Yet none of that
undercuts the legitimacy or validity of the construct, or of the
conclusions one can make about the current status of the
consistency of the evidence. ADHD is a neurodevelopmental and
heritable disorder with a lifespan perspective: starting in
childhood, persisting in adulthood until old age, with significant
psychosocial impairment, a high comorbidity rate and multi-
morbidity. It is associated with high levels of personal distress, and
a substantial economic burden for society if left unidentified and
untreated. DSM-5 has changed some of the criteria that facilitate
the diagnosis in adolescents and adults. Assessment should include
a detailed account of the developmental history, of both current
and retrospective ADHD symptoms and impairment, and associ-
ated comorbidities. To prevent under-reporting of symptoms,
external validation is desirable by collateral information. Multi-
modal treatment is required, comprising of psychoeducation,
pharmacotherapy, and cognitive behavior therapy and/or coach-
ing. Psychoeducational European programs to combat stigma and
to inform the public and (mental) health professionals about new
knowledge on the lifespan perspective of ADHD are needed to
improve and increase diagnostic and treatment services for adult
ADHD. Research on the different presentation of ADHD in women,
and on treatment of ADHD in old age should be further developed
in order to improve their treatment options.
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